Bell Rock Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Bell Rock Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-298	Closed	-$2K	–	277
2019 Q4	$2K	Hold	298	–	–	﹤0.01%	352
2019 Q3	$2K	Hold	298	–	–	﹤0.01%	331
2019 Q2	$2K	Hold	298	–	–	﹤0.01%	340
2019 Q1	$4K	Hold	298	–	–	﹤0.01%	366
2018 Q4	$4K	Hold	298	–	–	﹤0.01%	382
2018 Q3	$6K	Sell	298 -78	-21%	-$1.81K	﹤0.01%	380
2018 Q2	$9K	Hold	376	–	–	﹤0.01%	379
2018 Q1	$6K	Hold	376	–	–	﹤0.01%	396
2017 Q4	$7K	Hold	376	–	–	﹤0.01%	377
2017 Q3	$7K	Hold	376	–	–	﹤0.01%	357
2017 Q2	$12K	Buy	376 +1	+0.3%	+$31	0.01%	328
2017 Q1	$12K	Buy	375 +1	+0.3%	+$34	0.01%	294
2016 Q4	$14K	Buy	+374	New	+$14.9K	0.01%	273

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Bell Rock Capital's TEVA Position: Q1 2020 in Review

Bell Rock Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2020, closing a stake of 298 shares — an estimated $2K sold.

Bell Rock Capital first reported a position in TEVA in Q4 2016 and held it in 13 quarters. The position peaked at $14K in Q4 2016. 459 funds tracked by Wall St. Rank hold TEVA as of Q1 2020.

Bell Rock Capital reported no remaining Teva Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Bell Rock Capital sold 298 Teva Pharmaceuticals shares in Q1 2020, an estimated $2K.
Bell Rock Capital first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 13 quarters.
Bell Rock Capital's Teva Pharmaceuticals position peaked at $14K in Q4 2016.
459 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2020.

Based on Bell Rock Capital's 13F filing for Q1 2020, filed 7 May 2020.